AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Subscribe To Our Newsletter & Stay Updated